Etisulergine
Appearance
![]() | |
Clinical data | |
---|---|
Other names | CQ-32084; CQ 32-084; N,N-Diethyl-N'-(6-methylergolin-8α-yl)sulfamide |
Drug class | Dopamine agonist; Prolactin inhibitor; Antiparkinsonian agent |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H28N4O2S |
Molar mass | 376.52 g·mol−1 |
3D model (JSmol) | |
| |
|
Etisulergine (INN ; developmental code name CQ-32084 or CQ 32-084) is a drug of the ergoline family described as a dopamine agonist, prolactin inhibitor, and antiparkinsonian agent which was never marketed.[1][2][3][4][5][6] It is closely related in chemical structure to lisuride and is also similar in structure to lysergic acid diethylamide (LSD).[1][2] Etisulergine was first described in the literature by at least 1977.[1][5]
See also
[edit]References
[edit]- ^ a b c Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 524. ISBN 978-1-4757-2085-3. Retrieved 30 June 2025.
- ^ a b Negwer M, Scharnow H (2001). Organic-chemical Drugs and Their Synonyms: An International Survey. Organic-chemical Drugs and Their Synonyms: An International Survey. Wiley-VCH. p. 1829. ISBN 978-3-527-30247-5. Retrieved 30 June 2025.
- ^ Milne GW (8 May 2018). Drugs: Synonyms and Properties: Synonyms and Properties. Routledge. ISBN 978-1-351-78989-9. Retrieved 30 June 2025.
- ^ Casagrande C, Bertolini G (1996). "Perspectives in the design and application of dopamine receptor agonists". Pharmacochemistry Library. Vol. 24. Elsevier. pp. 67–84. doi:10.1016/s0165-7208(96)80008-0. ISBN 978-0-444-82204-8. Retrieved 30 June 2025.
- ^ a b Flückiger E, Briner U, Bürki HR, Marbach P, Wagner HR, Doepfner W (December 1979). "Two novel prolactin release-inhibiting 8 alpha-amino-ergolines". Experientia. 35 (12): 1677–1678. doi:10.1007/BF01953267. PMID 520501.
- ^ Pakkenberg H, Jensen I (1983). "Treatment of Parkinson's disease with the ergoline derivatives CQ 32-084 and CU 32-085". Advances in Neurology. 37: 151–157. PMID 6344587.